Why the study?
Does elevated plasma β-hydroxybutyrate predict MACE and disease progression in patients with arrhythmogenic cardiomyopathy and their relatives?
Does elevated plasma β-hydroxybutyrate predict MACE and disease progression in patients with arrhythmogenic cardiomyopathy and their relatives?
Elevated plasma β-hydroxybutyrate may serve as a useful biomarker for predicting adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy and their at-risk relatives.
Hypothesis-generating for β-OHB in AC family screening; prospective validation required before any clinical adoption.
< 0.001). Among 94 relatives of probands, higher plasma β-OHB distinguished 25 relatives having suspected AC from nonaffected relatives. This study demonstrates that elevated plasma β-OHB predicts MACE in probands and disease progression in patients with AC and their clinically asymptomatic relatives.
No takes yet. Share an insight, caveat, or question.
Song et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: